Catalyst Pharmaceuticals

Yahoo Finance • 13 days ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals

The practice of value investing centers on identifying companies trading below their intrinsic worth, a strategy pioneered by Benjamin Graham and later refined by investors like Warren Buffett. This approach emphasizes purchasing securitie... Full story

Yahoo Finance • 16 days ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX [https://www.chartmill.com/stock/quote/CPRX]) has appeared as a noteworthy candidate for investors using a Growth At Reasonable Price (GARP) strategy, which looks for companies showing strong growt... Full story

Yahoo Finance • 22 days ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX [https://www.chartmill.com/stock/quote/CPRX]) has appeared as a notable candidate via the Caviar Cruise stock screening method, a systematic process made to find high-quality companies suitable for... Full story

Yahoo Finance • 28 days ago

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 30 days ago

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals settles lawsuit with Lupin

[law legal] utah778/iStock via Getty Images Catalyst Pharmaceuticals (NASDAQ:CPRX [https://seekingalpha.com/symbol/CPRX]) said that the company and licensor SERB S.A. signed a settlement agreement with Lupin Pharmaceuticals, putting an en... Full story

Yahoo Finance • last month

Catalyst settles patent dispute with Lupin over FIRDAPSE

CORAL GABLES, Fla. - Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a $2.58 billion market cap biopharmaceutical company with an impressive 83% gross profit margin, announced Monday it has reached a settlement agreement with Lupin Ltd and L... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Value Investment in Biotech

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX [https://www.chartmill.com/stock/quote/CPRX]) presents a strong case for value investors looking for chances in the biotechnology sector. The company was found using a screening method that focuses... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Top Affordable Growth Stock with Strong Fundamentals

Investors looking for growth opportunities at fair prices often consider the "Affordable Growth" strategy, which finds companies with good growth prospects, steady profits, and strong finances, all while trading at reasonable prices. This... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaf... Full story

Yahoo Finance • 2 months ago

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with Breakout Potential

Combining technical and fundamental analysis can be an effective method for spotting growth stocks with promising breakout potential. The strategy targets stocks showing solid business growth, backed by strong profitability and financial s... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Value Stock with Strong Fundamentals and Growth Potential

Value investing centers on finding stocks priced below their true worth, giving investors a safety cushion. This approach, introduced by Benjamin Graham and further developed by Warren Buffett, highlights financial stability, earnings pote... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 4 months ago

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews wi... Full story

Yahoo Finance • 5 months ago

Catalyst: Q1 Earnings Snapshot

CORAL GABLES, Fla. (AP) — CORAL GABLES, Fla. (AP) — Catalyst Pharmaceutical Partners Inc. (CPRX) on Wednesday reported first-quarter profit of $56.7 million. The Coral Gables, Florida-based company said it had profit of 45 cents per share... Full story

Yahoo Finance • 5 months ago

Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy Now

We recently published a list of 11 Stocks with Consistent Growth to Buy Now. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against stocks with consistent growth to buy now. The m... Full story

Yahoo Finance • 5 months ago

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel... Full story